SUCCESSFUL ALLOGENEIC TRANSPLANTATION OF T-CELL DEPLETED BONE-MARROW FROM CLOSELY HLA-MATCHED UNRELATED DONORS

被引:294
作者
ASH, RC
CASPER, JT
CHITAMBAR, CR
HANSEN, R
BUNIN, N
TRUITT, RL
LAWTON, C
MURRAY, K
HUNTER, J
BAXTERLOWE, LA
GOTTSCHALL, JL
OLDHAM, K
ANDERSON, T
CAMITTA, B
MENITOVE, J
机构
[1] MED COLL WISCONSIN, DEPT MED, MILWAUKEE, WI 53226 USA
[2] MED COLL WISCONSIN, DEPT PEDIAT, MILWAUKEE, WI 53226 USA
[3] MED COLL WISCONSIN, DEPT RADIAT ONCOL, MILWAUKEE, WI 53226 USA
[4] MED COLL WISCONSIN, DEPT PATHOL, MILWAUKEE, WI 53226 USA
[5] BLOOD CTR SE WISCONSIN INC, MILWAUKEE, WI USA
关键词
D O I
10.1056/NEJM199002223220801
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe a four-year experience with bone marrow transplantation involving closely HLA-matched unrelated donors and 55 consecutive patients with hematologic disease who were seven months to 48.6 years old (median, 18 years). An intensive pretransplantation conditioning regimen and graft-versus-host disease (GVHD) prophylaxis with CD3-directed T-cell depletion and cyclosporine were employed. Durable engraftment was achieved in 50 of 53 patients who could be evaluated (94 percent; 95 percent confidence interval, 83 to 98 percent). Acute GVHD of Grade II to IV developed in 46 percent of the patients (confidence interval, 27 to 66 percent). The incidence and severity of acute GVHD were increased in recipients of HLA-mismatched marrow as compared with recipients of phenotypically matched marrow (incidence of 53 percent [confidence interval, 37 to 68 percent] vs. 17 percent [confidence interval, 5 to 45 percent]; P<0.05). Extensive chronic GVHD and deaths not due to relapse also tended to be more frequent when HLA-mismatched marrow was used, but not significantly so. With a median follow-up of more than 19 months (range, >9 to >39), the actuarial disease-free survival of transplant recipients with leukemia and a relatively good prognosis (acute leukemia in first remission and chronic myelogenous leukemia in chronic phase) was 48 percent (confidence interval, 24 to 73 percent), and that of recipients with more aggressive leukemia was 32 percent (confidence interval, 18 to 51 percent); the actuarial survival of recipients with non-neoplastic disease was 63 percent (confidence interval, 31 to 86 percent). We conclude that marrow transplantation with closely HLA-matched unrelated donors can be effective treatment for neoplastic and non-neoplastic diseases. Although transplants from phenotypically HLA-matched unrelated donors appear to be most effective, transplants with limited HLA disparity can also be successful in some patients. (N Engl J Med 1990; 322:485–94.). © 1990, Massachusetts Medical Society. All rights reserved.
引用
收藏
页码:485 / 494
页数:10
相关论文
共 78 条
[1]   EFFECT OF HLA COMPATIBILITY ON ENGRAFTMENT OF BONE-MARROW TRANSPLANTS IN PATIENTS WITH LEUKEMIA OR LYMPHOMA [J].
ANASETTI, C ;
AMOS, D ;
BEATTY, PG ;
APPELBAUM, FR ;
BENSINGER, W ;
BUCKNER, CD ;
CLIFT, R ;
DONEY, K ;
MARTIN, PJ ;
MICKELSON, E ;
NISPEROS, B ;
OQUIGLEY, J ;
RAMBERG, R ;
SANDERS, JE ;
STEWART, P ;
STORB, R ;
SULLIVAN, KM ;
WITHERSPOON, RP ;
THOMAS, ED ;
HANSEN, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (04) :197-204
[2]   HIGH-RESOLUTION ANALYSIS OF THE HUMAN HLA-DR POLYMORPHISM BY HYBRIDIZATION WITH SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBES [J].
ANGELINI, G ;
DEPREVAL, C ;
GORSKI, J ;
MACH, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (12) :4489-4493
[3]  
ASH RC, 1987, UCLA S MOL CELLULAR, V53, P365
[4]  
ASH RC, 1988, BLOOD S, V72, pA378
[5]  
ASH RC, 1989, UCLA S MOL CELLULAR, V91, P629
[6]  
ASH RC, 1988, EXP HEMATOL, V16, P470
[7]  
ASH RC, 1986, BLOOD S, V68, pA279
[8]  
ATKINSON K, 1982, BLOOD, V60, P714
[9]  
AWDEH ZL, 1985, LANCET, V2, P853
[10]  
BACIGALUPO A, 1988, BONE MARROW TRANSPL, V3, P531